Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Neoplasma (Bratislava)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12088105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The value of cysteinyldopa in the follow-up of disseminated malignant melanoma

  2000cited by this paper
• Serum concentration of 5‐S‐cysteinyldopa in patients with melanoma

  2000cited by this paper
• Clinical significance of S-100 protein assay in malignant melanoma

  1999cited by this paper
• MIA, a novel serum marker for progression of malignant melanoma.

  1999cited by this paper
• Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.

  1999cited by this paper
• Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children.

  1998cited by this paper
• Clinical and prognostic relevance of serum S‐100β protein in malignant melanoma

  1998cited by this paper
• Prognostic value of serum analyses of S-100 protein beta in malignant melanoma.

  1997cited by this paper
• Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

  1997cited by this paper
• Serum levels of slCAM-1 and 5-S-cysteinyldopa as markers of melanoma progression

  1997cited by this paper
• Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.

  1997cited by this paper
• Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma

  1997cited by this paper
• Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.

  1997cited by this paper
• Evaluation of new putative tumor markers for melanoma

  1996cited by this paper
• Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells

  1996cited by this paper
• Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.

  1996cited by this paper
• Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese.

  1995cited by this paper
• Evaluation of melanin‐related metabolites as markers of melanoma progression

  1994cited by this paper
• Correlation between Lipid-Associated Sialic Acid and Tumor Burden in Melanoma

  1994cited by this paper
• Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.

  1988cited by this paper
• Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.

  1988cited by this paper
• 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.

  1979cited by this paper
• The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

  1969cited by this paper
• [Determination of uric acid in serum].

  1966cited by this paper

• Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients

  2011cites this paper
• Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of Melanoma

  2007cites this paper
• A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients

  2007cites this paper
• Combination hepatic arterial infusion therapy is effective for ocular melanoma metastasis to the liver.

  2005cites this paper
• Improved method for analysis of cysteinyldopa in human serum

  2004cites this paper
• Biomarkers in melanoma: staging, prognosis and detection of early metastases

  2003cites this paper